{"id":"NCT04620135","sponsor":"Aerie Pharmaceuticals","briefTitle":"Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","officialTitle":"A Single-masked, Randomized, Multi-center, Parallel-group, 4-week Study Evaluating the Efficacy and Safety of Once Daily Netarsudil Ophthalmic Solution 0.02% Compared to Twice Daily Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% in Japanese Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-11-30","primaryCompletion":"2021-07-09","completion":"2021-07-30","firstPosted":"2020-11-06","resultsPosted":"2023-02-27","lastUpdate":"2023-02-27"},"enrollment":245,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Primary Open Angle Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"Netarsudil ophthalmic solution 0.02%","otherNames":["Vehicle: Netarsudil ophthalmic solution"]},{"type":"DRUG","name":"Ripasudil hydrochloride hydrate ophthalmic solution 0.4%","otherNames":[]}],"arms":[{"label":"Netarsudil ophthalmic solution 0.02% and netarsudil ophthalmic solution vehicle","type":"EXPERIMENTAL"},{"label":"Ripasudil hydrochloride hydrate ophthalmic solution 0.4%","type":"ACTIVE_COMPARATOR"}],"summary":"A Phase 3 Study Comparing the Efficacy and Safety of Netarsudil Ophthalmic Solution 0.02% QD to Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% BID, for Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Over A 4-Week Period.","primaryOutcome":{"measure":"Intraocular Pressure (IOP)","timeFrame":"29 Days","effectByArm":[{"arm":"Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle","deltaMin":15.96,"sd":0.157},{"arm":"Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%","deltaMin":17.71,"sd":0.155}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.00001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":17},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["37603205"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":122},"commonTop":["Conjunctival hyperaemia","Eye irritation"]}}